Project Details
Description
A 12-month, randomized, open-label, phase IIA study evaluating the safety and efficacy of siplizumab in combination with belatacept and MMF compared to standard of care immunosuppression in de novo renal transplant recipients (ASCEND)
| Status | Active |
|---|---|
| Effective start/end date | 9/29/22 → 12/31/26 |
Funding
- ITB-MED, LLC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.